COVID-19 vaccines administered by age group in Colombia

Vacunas contra COVID-19 aplicadas por grupo de edad en Colombia

Introduction: thousands of dollars are being invested for research on COVID 19 pathogenesis, treatment and prevention. To prevent COVID 19, at least 90 vaccines have been developed with the hope for providing immunity. Objective: to describe the progression of SARS-COV-2 full vaccination by age group by territorial entity in Colombia, in the period between February 17 and August 21 2021. Methodology: an analytical cross-sectional study specifically designed to gather information on vaccines administered in Colombia by age group; using the information released in the Ministry of Health and Social Protection webpage based on the COVID 19 national vaccination plan. Results: the highest full vaccination by age group was found in people in the 50 to 59 years (2’089.980), 60 to 69 years (1’937.880), and 40 to 49 years (1’480.711) age groups. The lowest number of completed vaccination protocols by age group was found in the:12 to 19 years (55.113), 20 to 29 years (476.866) and 30 to 39 years (624.909) age groups. Conclusion: currently vaccination is the most important intervention to bring the pandemic to an end. However, the emergence of multiple SARS-COV-2 variants with reduced susceptibility to vaccine-induced immunity makes the disease to remain a threat to progress.

1. Callaway E. The race for coronavirus vaccines: a graphical guide. Naturaleza. Nature. 2020;580(7805):576-577. doi: 10.1038/d41586-020-01221-y
2. Declaración de la FDA sobre el seguimiento de los programas de dosificación autorizados para las vacunas COVID-19 [Interne]. 2021 [citado 26 enero de 2021]. Disponible en: https://www.fda.gov/news-events/press-announcements/declaracion-de-la-fda-sobre-el-seguimiento-de-los-programas-de-dosificacion-autorizados-para-las
3. Vi C Do T, Thota Kammili S, Reep M, Wisnieski L, Shyam Ganti S, Depa J. COVID-19 Vaccine Acceptance Among Rural Appalachian Healthcare Workers (Eastern Kentucky/West Virginia): A Cross-Sectional Study. Cureus. 2021;13(8):e16842. doi: 10.7759/cureus.16842
4. Dror AA, Eisenbach N, Taiber S, Morozov NG, et al. Vaccine hesitancy: the next challenge in the fight against COVID-19. Eur J Epidemiol. 2020;35(8):775-779. doi: 10.1007/s10654-020-00671-y
5. Wang J, Jing R, Lai X, Zhang H, Lyu Y, Knoll MD, Fang H. Acceptance of COVID-19 Vaccination during the COVID-19 Pandemic in China. Vaccines (Basel). 2020;8(3):482. doi: 10.3390/vaccines8030482
6. Neumann-Böhme S, Varghese NE, Sabat I, Pita Barros P, et al. Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19. Eur J Health Econ. 2020;21(7):977-982. doi: 10.1007/s10198-020-01208-6
7. Fisher KA, Bloomstone SJ, Walder J, Crawford S, Fouayzi H, Mazor KM. Attitudes Toward a Potential SARS-CoV-2 Vaccine : A Survey of U.S. Adults. Ann Intern Med. 2020;173(12):964-973. doi: 10.7326/M20-3569
8. Reiter PL, Pennell ML, Katz ML. Acceptability of a COVID-19 vaccine among adults in the United States: How many people would get vaccinated?. Vaccine. 2020;38(42):6500-6507. doi: 10.1016/j.vaccine.2020.08.043
9. Dror AA, Eisenbach N, Taiber S, Morozov NG, Mizrachi M, Zigron A, et al. Vaccine hesitancy: the next challenge in the fight against COVID-19. Eur J Epidemiol. 2020;35(8):775–779. doi: 10.1007/s10654-020-00671-y
10. The European Centre for Disease Prevention and Control (ECDC). Vaccine hesitancy [Internet]. European Centre for Disease Prevention and Control; 2017 [cited 2021 Jun 27]. Available from: https://www.ecdc.europa.eu/en/immunisation-vaccines/vaccine-hesitancy
11. Karafillakis E, Dinca I, Apfel F, Cecconi S, Wűrz A, Takacs J, et al. Vaccine hesitancy among healthcare workers in Europe: A qualitative study. Vaccine. 2016;34(41):5013–20. doi: 10.1016/j.vaccine.2016.08.029
12. Ministerio de Salud y Protección Social de Colombia. Plan de vacunación nacional contra COVID-19 [Internet]. 2021 [citado 27 enero 2021]. Disponible en: https://www.minsalud.gov.co/salud/publica/Vacunacion/Paginas/Vacunacion-covid-19.aspx
13. Díaz Pinzón JE. Estimación de la prevalencia del COVID-19 en Colombia. Repert Med Cir. 2020;29(Núm. Supl.1):99–102. https://doi.org/10.31260/RepertMedCir.01217372.1115
14. Díaz Pinzón JE. Análisis de los resultados del contagio del COVID-19 respecto a su distribución geográfica en Colombia. Repert Med Cir. 2020;29(Núm. Supl.1):60–64. https://doi.org/10.31260/RepertMedCir.01217372.1082
15. Díaz Pinzón JE. Dinámica y relación del contagio del COVID-19 después de iniciado el plan de vacunación contra el SARS-COV-2 en Colombia. Repert Med Cir. 2021;30(Núm. Supl.1):41–45. https://doi.org/10.31260/RepertMedCir.01217372.1227
16. Creech CB, Walker SC, Samuels RJ. SARS-CoV-2 Vaccines. JAMA. 2021;325(13):1318–1320. doi: 10.1001/jama.2021.3199